Effects of Early Inhaled Epoprostenol Therapy on Pulmonary Artery Pressure and Blood Loss During LVAD Placement

• Published in: Journal of cardiothoracic and vascular anesthesia Vol. 28; no. 3; pp. 652 - 660
• Main Authors: Groves, Danja S., MD, PhD, Blum, Franziska E., MD, Huffmyer, Julie L., MD, Kennedy, Jamie L.W., MD, Ahmad, Hasan B., BS, Durieux, Marcel E., MD, PhD, Kern, John A., MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2014
• Subjects: Administration, Inhalation; Aged; Aged, 80 and over; Anesthesia & Perioperative Care; Arterial Pressure - drug effects; Blood Coagulation - drug effects; blood loss; Blood Loss, Surgical - prevention & control; Blood Transfusion - statistics & numerical data; Critical Care; Epoprostenol - administration & dosage; Epoprostenol - therapeutic use; Female; Heart-Assist Devices; Humans; inhaled epoprostenol; left ventricular assist device; Male; Middle Aged; prostacyclin; Pulmonary Artery - drug effects; pulmonary artery pressure; Retrospective Studies; Vasodilator Agents - administration & dosage; Vasodilator Agents - therapeutic use; left ventricular assist device; pulmonary artery pressure; prostacyclin; blood loss; inhaled epoprostenol

Objective Several strategies have been used to reduce the incidence of right ventricular failure after left ventricular assist device (LVAD) placement, including pulmonary vasodilation. The inhaled prostacyclin, epoprostenol, selectively dilates the pulmonary vasculature of ventilated areas of the l...